Description: Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Home Page: pharnext.com
14 rue de la REpublique
Suresnes,
92150
France
Phone:
33 1 41 09 22 30
Officers
| Name | Title |
|---|---|
| Mr. Daniel E. Cohen M.D., Ph.D. | Director |
| Mr. Hugo Brugiere M.Sc. | CEO & Chairman |
| Mr. Ilya Chumakov D-Sc, Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Director |
| Mr. Vincent Serra Ph.D. | COO & Chief Scientific Officer |
| Mr. Raj Thota M.Sc. | Chief Manufacturing Officer & Head of CMC |
| Mr. Gilbert Wagener M.D., Ph.D. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 25.3623 |
| Price-to-Sales TTM: | 0.162 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |